神経内分泌がん(Neuroendocrine Carcinoma):世界の治験レビュー(2015年上半期版)

◆英語タイトル:Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2015
◆商品コード:GDHC2620CTIDB
◆発行会社(リサーチ会社):GlobalData
◆発行日:2015年3月27日
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD7,500 ⇒換算¥847,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における神経内分泌がん(Neuroendocrine Carcinoma) 治療の臨床試験動向について調査・分析し、アジア太平洋/欧州/北米/中南米の主要国における治験件数、段階(フェーズ)別の治験件数、進捗状況別の治験件数、治験目標の達成状況、有望な薬剤、治験関連の最新ニュース、代表的な企業・大学・研究機関における治験概要、代表的な治験のプロファイルなどのデータをまとめてお届けいたします。

・イントロダクション
  - 神経内分泌がん(Neuroendocrine Carcinoma)
  - 当レポートの概要
・神経内分泌がん(Neuroendocrine Carcinoma):各地域別治験状況
  - 各国の治験件数及び平均被験者数
   アジア太平洋の主要国における治験件数
   欧州の主要国における治験件数
   北米の主要国における治験件数
   中東・アフリカの主要国における治験件数
   中南米の主要国における治験件数
・G7諸国での治験件数
・G7諸国での治験件数:段階別
・G7諸国での治験件数:進捗状況別
・段階(フェーズ)別の治験件数:進行中の治験(段階別)
・進捗状況別の治験件数
・治験目標の達成状況
・未完了の治験件数
・一定期間に採用された被験者
・スポンサーの種類別治験件数
・有望なスポンサー
・有望な薬剤
・治験のプロファイル
  - 代表的な企業における治験概要
  - 代表的な大学・研究機関における治験概要
・5つの代表的な治験のプロファイル
【レポートの概要】

Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2015

Summary

GlobalData’s clinical trial report, “Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2015″ provides data on the Neuroendocrine Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroendocrine Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Neuroendocrine Carcinoma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Neuroendocrine Carcinoma to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Neuroendocrine Carcinoma 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Top Companies Participating in Neuroendocrine Carcinoma Therapeutics Clinical Trials 25
Prominent Drugs 26
Clinical Trial Profiles 27
Clinical Trial Overview of Top Companies 27
Pfizer Inc. 27
Clinical Trial Overview of Pfizer Inc. 27
Novartis AG 28
Clinical Trial Overview of Novartis AG 28
Philogen S.p.A. 29
Clinical Trial Overview of Philogen S.p.A. 29
Clinical Trial Overview of Top Institutes / Government 30
National Cancer Institute 30
Clinical Trial Overview of National Cancer Institute 30
The University of Texas M. D. Anderson Cancer Center 31
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 31
Fondazione IRCCS – Istituto Nazionale dei Tumori 32
Clinical Trial Overview of Fondazione IRCCS – Istituto Nazionale dei Tumori 32
Japan Clinical Oncology Group 33
Clinical Trial Overview of Japan Clinical Oncology Group 33
Alberta Health Services 34
Clinical Trial Overview of Alberta Health Services 34
Centre Hospitalier Universitaire de Grenoble 35
Clinical Trial Overview of Centre Hospitalier Universitaire de Grenoble 35
Chiba University 36
Clinical Trial Overview of Chiba University 36
Gabrail Cancer Center 37
Clinical Trial Overview of Gabrail Cancer Center 37
Five Key Clinical Profiles 38
Appendix 63
Abbreviations 63
Definitions 63
Research Methodology 64
Secondary Research 64
About GlobalData 65
Contact Us 65
Disclaimer 65
Source 65

List of Tables
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Region, 2015* 7
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Neuroendocrine Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 13
Proportion of Neuroendocrine Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2015* 14
Neuroendocrine Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Neuroendocrine Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2015* 17
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 18
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 19
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 20
Neuroendocrine Carcinoma Therapeutics, Global, Suspended Clinical Trials, 2015* 21
Neuroendocrine Carcinoma Therapeutics, Global, Withdrawn Clinical Trials, 2015* 21
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 22
Neuroendocrine Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 23
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 24
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 25
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 26
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 27
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 28
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Philogen S.p.A., 2015* 29
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 30
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2015* 31
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fondazione IRCCS - Istituto Nazionale dei Tumori, 2015* 32
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Japan Clinical Oncology Group, 2015* 33
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Alberta Health Services, 2015* 34
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Centre Hospitalier Universitaire de Grenoble, 2015* 35
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Chiba University, 2015* 36
Neuroendocrine Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Gabrail Cancer Center, 2015* 37

List of Figures
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 10
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Neuroendocrine Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Proportion of Neuroendocrine Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2015* 14
Neuroendocrine Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Neuroendocrine Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2015* 17
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 18
Neuroendocrine Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 19
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 20
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 22
Neuroendocrine Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 23
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 24
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 25
Neuroendocrine Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 26
GlobalData Methodology 64

【レポートのキーワード】

神経内分泌がん(Neuroendocrine Carcinoma)、治験、臨床試験、治験、治療薬

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[神経内分泌がん(Neuroendocrine Carcinoma):世界の治験レビュー(2015年上半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆